Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA vaccines for hepatitis C virus.

C Brinster1, G Inchauspé

  • 1INSERM U271, Lyon, France. brinster@lyon151.inserm.fr

Intervirology
|August 18, 2001
PubMed
Summary

Developing a Hepatitis C virus (HCV) vaccine is crucial due to limited therapies. Current DNA vaccines poorly induce long-lasting antibody responses, highlighting a need for improved vaccine strategies against this chronic RNA virus.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.

Journal of viral hepatitis·2017
Same author

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.

Gene therapy·2016
Same author

Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4+CD25hiFoxp3+ regulatory T cells.

Clinical immunology (Orlando, Fla.)·2008
Same author

Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.

Journal of viral hepatitis·2007
Same author

An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.

Vaccine·2007
Same author

Primary and memory T cell responses induced by hepatitis C virus multiepitope long peptides.

Vaccine·2006

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Hepatitis C virus (HCV) is an RNA virus from the Flaviviridae family.
  • Chronic HCV infection can lead to cirrhosis and hepatocellular carcinoma over 20-30 years.
  • Existing therapies for HCV are expensive and offer limited benefits, necessitating vaccine development.

Purpose of the Study:

  • To address the urgent need for an effective Hepatitis C virus vaccine.
  • To investigate the limitations of current vaccine technologies in eliciting protective immune responses.
  • To understand the role of humoral and cellular immunity in controlling HCV infection.

Main Methods:

  • Review of current scientific literature on HCV virology and immunology.
  • Analysis of existing DNA-based vaccine platforms and their efficacy.
  • Evaluation of immune correlates of protection against Hepatitis C virus.

Main Results:

  • Hepatitis C virus infections frequently become chronic, posing long-term health risks.
  • Both antibody (humoral) and T-cell (cellular) immune responses are implicated in controlling HCV.
  • Current DNA-based vaccines show limitations in generating robust and sustained antibody responses.

Conclusions:

  • A preventative vaccine for Hepatitis C virus is a high priority.
  • Effective HCV vaccines must induce both strong humoral and cellular immunity.
  • Further research is needed to overcome the limitations of current vaccine strategies for Hepatitis C virus.

Related Experiment Videos